Aldosterone Blockade Early After Acute Myocardial Infarction
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1603 participants.
Also called NCT01059136
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; no masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 1,603 participants
- Registry
-
NCT01059136
-
- Other papers using this trial's data
- Early Aldosterone Blockade in Acute Myocardial Infarction: The ALBATROSS Randomized Clinical Trial
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- France
- Registry status
- Completed
Technical summary
Registry record NCT01059136. Randomized; no masking; primary purpose treatment. Start 2010-02 (registry gives no type); primary completion 2014-08 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Aldosterone Blockade Early After Acute Myocardial Infarction
- Acronym
- ALBATROSS
- Condition
- Myocardial Infarction
- Intervention (Drug)
- Spironolactone
- Lead sponsor
- Assistance Publique - Hôpitaux de Paris
Record details
- Record id
cardio:ct-nct01059136- Content hash
6dc60117d0efb17b26e54672e6249f48ac66dcc464d083c5a8c7e3362d692e0f